Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease

V. Bachanova, D. I. Marks, M. J. Zhang, H. Wang, M. De Lima, M. D. Aljurf, M. Arellano, A. S. Artz, U. Bacher, J. Y. Cahn, Y. B. Chen, E. A. Copelan, W. R. Drobyski, R. P. Gale, J. P. Greer, V. Gupta, G. A. Hale, P. Kebriaei, H. M. Lazarus, I. D. LewisV. A. Lewis, J. L. Liesveld, M. R. Litzow, A. W. Loren, A. M. Miller, M. Norkin, B. Oran, J. Pidala, J. M. Rowe, B. N. Savani, W. Saber, R. Vij, E. K. Waller, P. H. Wiernik, D. J. Weisdorf

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Immunology and Microbiology